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A simple method for sphingolipid analysis of tissues
embedded in optimal cutting temperature compound
Timothy D. Rohrbach,1,* April E. Boyd,† Pamela J. Grizzard,§ Sarah Spiegel,*
Jeremy Allegood,*,** and Santiago Lima2,†,††
Department of Biochemistry and Molecular Biology,* Virginia Commonwealth University, Richmond, VA
23298; Department of Biology,† Virginia Commonwealth University, Richmond, VA 23284; Tissue and Data
Acquisition and Analysis Core,§ Virginia Commonwealth University Massey Cancer Center,†† Richmond, VA
23298; and Virginia Commonwealth University Lipidomics/Metabolomics Shared Resource,** Virginia
Commonwealth University School of Medicine, Richmond, VA 23298
ORCID IDs: 0000-0003-0751-2634 (S.S.); 0000-0002-6949-7962 (S.L.)

Abstract MS-assisted lipidomic tissue analysis is a valuable
tool to assess sphingolipid metabolism dysfunction in disease. These analyses can reveal potential pharmacological
targets or direct mechanistic studies to better understand the
molecular underpinnings and influence of sphingolipid metabolism alterations on disease etiology. But procuring sufficient human tissues for adequately powered studies can be
challenging. Therefore, biorepositories, which hold large
collections of cryopreserved human tissues, are an ideal retrospective source of specimens. However, this resource has
been vastly underutilized by lipid biologists, as the components of OCT compound used in cryopreservation are incompatible with MS analyses. Here, we report results
indicating that OCT compound also interferes with protein
quantification assays, and that the presence of OCT compound impacts the quantification of extracted sphingolipids
by LC-ESI-MS/MS. We developed and validated a simple
and inexpensive method that removes OCT compound from
OCT compound-embedded tissues. Our results indicate that
removal of OCT compound from cryopreserved tissues does
not significantly affect the accuracy of sphingolipid measurements with LC-ESI-MS/MS. We used the validated method to
analyze sphingolipid alterations in tumors compared with
normal adjacent uninvolved lung tissues from individuals
with lung cancer and to determine the long-term stability of
sphingolipids in OCT compound-cryopreserved normal lung
tissues. We show that lung cancer tumors have significantly
altered sphingolipid profiles and that sphingolipids are stable for up to 16 years in OCT compound-cryopreserved
normal lung tissues. This validated sphingolipidomic
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OCT compound-removal protocol should be a valuable addition to the lipid biologist’s toolbox.—Rohrbach, T. D., A.
E. Boyd, P. J. Grizzard, S. Spiegel, J. Allegood, and S. Lima. A
simple method for sphingolipid analysis of tissues embedded in optimal cutting temperature compound. J. Lipid Res.
2020. 61: 953–967.
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ceramide • lung adenocarcinoma • lung squamous cell carcinoma •
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Sphingolipids are structurally related lipid metabolites
with well-established roles in human physiology and disease (1, 2). Many are highly bioactive, and regulate complex biological programs like cellular migration, survival,
motility, intracellular vesicular trafficking, metastasis, angiogenesis, invasion, and cytokine production (1–9). Sphingolipid dysregulation is known to significantly contribute to
cancer initiation, progression, response to therapy, and the
development of multi-drug resistance (3, 10). Given this
broad impact on the etiology of disease, there is great interest in precisely establishing disease-specific sphingolipid
alterations.
A popular MS platform to quantify sphingolipids in cells
and tissues is LC-ESI-MS/MS (2, 3, 11–13). However, there
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are limitations to the types of tissue specimens that can be
analyzed. For example, it has not previously been shown
that LC-ESI-MS/MS can be used for the analysis of sphingolipids in tissues embedded in OCT compound. OCT
compound contains polyvinyl alcohol and polyethylene
glycol that readily ionize and result in ion suppression and
loss of signal in most MS platforms (14–17). Therefore, as
embedding tissues in OCT compound is one of the primary cryopreservation methods used by tissue biorepositories (18), the vast numbers of tissue specimens held by
these facilities have mostly remained untouched by sphingolipid biologists. In stark contrast, there are various methods developed for analyzing DNA, RNA, and proteins from
OCT compound-embedded tissues (14, 16, 19–22). However, most of these methods are unsuitable for the extraction and analysis of lipids, as many rely on organic solvents
or detergents, which would deplete sphingolipids during
the OCT compound-removal stages. Given that tissue biorepositories perform front-end quality control to confirm
histology and pathology, follow standard operating procedures to cryogenically store human tissue specimens, and
can access subjects’ clinical data that can be used to find
clinically relevant correlations between lipidomic data and
clinicopathological variables, biorepositories are ideal
specimen sources for molecular lipid research. Thus, it is
critical that methods are developed for sphingolipid biologists to take advantage of the excellent research materials
and resources that can be provided by tissue biorepositories. Here, we present a sphingolipidomic OCT compoundremoval protocol (sOCTrP) that makes it possible to
analyze sphingolipids in OCT compound-embedded tissues using LC-ESI-MS/MS.

MATERIALS AND METHODS
Human tissue specimens
De-identified human lung tissues were procured from the
Virginia Commonwealth University (VCU) Tissue and Data
Acquisition and Analysis Core (TDAAC) under a VCU IRBapproved protocol (#HM2471). Specimens were obtained during
standard-of-care procedures and banked when judged to be in
excess of that required for patient diagnosis and treatment.
Fresh samples procured during routine gross examination in
surgical pathology were deposited into 2 ml cryovials, snap-frozen in liquid nitrogen, and then stored at 80°C. These tissues
were then carefully evaluated for histological type, and then tissues were placed in plastic 24 × 5 mm round disposable base
molds (TissueTek, #NC0548726) and filled with OCT compound (Fisher, #23-730-571). OCT compound-embedded specimens were then sectioned, and representative hematoxylin and
eosin-stained sections were prepared for histological review by a
pathologist to determine the presence or lack of tumor. Only
tumor sections with greater than 35% tumor enrichment were
selected for lipidomics studies. Suitable samples were prepared
as 10 m frozen sections as needed. On average, 21.4 ± 8.9 mg
of tissue sections were prepared for lipidomic analysis. Frozen
tissue sections were placed into labeled 15 ml polypropylene
conical tubes and stored at 80°C. All associated anonymized
sample annotation was generated by the TDAAC SQL2000 secure biorepository database.
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Mouse lung and liver specimens
Liver. Mice were euthanized by CO2 inhalation followed by
cervical dislocation. Livers were removed en toto and dipped in
PBS to wash off excess blood. Livers were then mechanically
minced into six to eight pieces and rinsed with PBS. Minced liver
tissues were then placed in 2 ml cryovials and snap-frozen in liquid nitrogen or placed in disposable plastic pathology base molds
(Fisher, #22-363-554) containing 2 ml of OCT compound
(Fisher, #23-730-571), and then placed over a bed of dry ice until
frozen.
Lung. Mice were euthanized by CO2 inhalation followed by
cervical dislocation. Lungs were removed en toto and dipped in
PBS to wash off excess blood. Lungs were then separated into
right and left lobes, minced, washed with PBS, and placed into
2 ml cryovials and snap-frozen in liquid nitrogen, or placed in
disposable plastic pathology base molds (Fisher, #22-363-554)
containing 2 ml of OCT compound (Fisher, #23-730-571) and
then placed over a bed of dry ice until frozen. For each euthanized mouse, one snap-frozen lung control cryovial and one
OCT compound-embedded lung block were prepared. All
samples were stored at 80°C until they were processed for
lipidomics.

sOCTrP
Human lung specimens. Human tissues were processed in a
class II type A2 biosafety cabinet following safety protocols for
specimens of human origin. All steps were performed at 4°C or
on ice. Frozen sections of OCT compound-embedded lung tumors or adjacent uninvolved tissues (AUTs) in 15 ml polypropylene tubes were thawed on ice, and then 10 ml of ice-cold
ultra-pure deionized Milli-Q water (Millipore) were added. No
difference in sphingolipid quantification was observed if PBS or
water was used for washing tissues (data not shown). Tubes containing tissues were then vigorously vortexed (typically 20 s).
Samples were then centrifuged at 5,000 g and 4°C in a swinging
bucket rotor for 10 min. Importantly, 15 ml conical tubes containing human specimens were centrifuged in swinging buckets
equipped with ClickSeal biocontainment lids (Thermo Fisher,
#75007309) to avoid potential exposure to biohazardous aerosols generated during centrifugation. Following centrifugation,
the supernatant was aspirated with great care to avoid taking up
any tissue. This was considered one standard sOCTrP cycle. If
more sOCTrP cycles were required, 10 ml of ice-cold ultra-pure
deionized Milli-Q water were added, the samples vortexed, centrifuged, the supernatant aspirated, and the process repeated
until all cycles had been completed. After the final aspiration
step, the tissues were resuspended in 500 l of ice-cold potassium phosphate buffer (Gibco, #20012027). Milli-Q water could
also be used, but in practice PBS maximized the amount of tissue that could be retrieved from the 15 ml conical tube. Moreover, to assist in the transfer of lung sections from the 15 ml
tubes, 4–5 mm of the tip of a 1,000 l pipette tip (TipOne,
#1111-2721) were cut off using clean surgical scissors prerinsed
with methanol, and the shortened tip used to resuspend and
uptake the finely sectioned washed lung tissues. Tissues were
then placed into preweighed and labeled 1.5 ml polypropylene
micro-centrifuge tubes (USA Scientific, #1615-5500). Tube preweighing was done in an analytical balance and the weights recorded in an electronic spreadsheet. The preweighed 1.5 ml
tubes containing the samples in PBS were then centrifuged at
7,500 g and 4°C for 10 min. The tubes were then retrieved and
the supernatant carefully aspirated. Prior to reweighing the
tubes, a fine wick formed by twisting the corner of a Kimwipe tissue
(Kimtech, #34120) was used to carefully remove all remaining

aqueous solution. Touching specimens with the wick was avoided
to prevent contamination and tissues adhering to the wick.
However, in control experiments, Kimwipes were processed
with the lipid extraction protocol and analyzed with LC-ESIMS/MS. Kimwipes inherently are low shedding, but at theoretical shedding quantities of 0.1 to 0.5 mm2, which is likely
hundreds of times the amount of potential Kimwipe contamination, there were negligible amounts of sphingolipids (data not
shown). After aspirating and wicking as much aqueous solution
as possible, tubes were reweighed in an analytical balance and
weights recorded in an electronic spreadsheet. Tissue weight
was calculated by subtracting the weight of tube with tissue specimen from the weight of the tube without tissue specimen and
considered “wet weight”. In control experiments, wet weight and
initial tissue weights were highly and significantly correlated (see
Fig. 1A), as were wet weight and protein concentration from tissues (see Fig. 1B), indicating that wet weight is an accurate measure of original tissue weights. After weighing, 300 l of ice-cold
PBS were added to the tube, and a shortened pipette was used to
retrieve the samples and place them in 1 ml of LC-MS grade icecold methanol in a 13 × 100 mm screw-top glass tube (VWR,
#53283-800) that was then capped (Kimble, #45066C-13). Tissues
in methanol were stored at 80°C until processed for sphingolipidomic analyses as described below.
Mouse lung and liver tissues. OCT compound-embedded and
frozen mouse tissues were thawed by placing base molds and
tubes over a bed of ice. Upon thawing, tissues were retrieved from
the OCT compound medium using forceps or a small spatula and
placed in 15 ml polypropylene conical tubes (USA Scientific
#14752610) containing 10 ml of prechilled ice-cold ultra-pure deionized water (Milli-Q; Millipore). Retrieving tissues out of the
OCT compound-embedding medium minimized the amount of
OCT compound carried over. All tissues were maintained at 4°C
post-thawing. All other sOCTrP steps were performed as described for human tissues above.

Lipid extraction
Tissues stored in methanol at 80°C were equilibrated to
room temperature (25°C) prior to processing, and 10 l of internal standard solution (see below) were added to each tube
with a mechanical repeating pipette (Eppendorf, Hauppauge,
NY). Tissues were then homogenized (Homogenizer 150, Fisher
Scientific) at maximum power until fully triturated (5–10 s).
To ensure that no tissue clumps remained, tubes were sonicated in a Branson 2800 series ultrasonic bath (Branson Ultrasonics, Danbury, CT). If any tissue aggregates formed upon
sonication, the samples were rehomogenized and the process
repeated iteratively until no more clumps formed upon sonication. Methanol and chloroform were then added to achieve
a 2:1:0.1 ratio of methanol:chloroform:water. Typically, an extraction volume of 3–4 ml was used for specimens weighing 50
mg or less and adjusted accordingly for larger specimens.
Tubes were then tightly recapped, and the single-phase BlighDyer mixture was incubated at 48°C overnight. The next
morning, tubes were centrifuged for 10 min at 4°C and 5,000
g to remove insoluble debris, and the supernatant decanted or
pipetted into clean 13 × 100 mm borosilicate glass tubes. Solvent was then evaporated under vacuum at 45°C in Speed-vac
equipped with a solvent condenser (Thermo Scientific). Extracted lipids were then reconstituted in 0.5 ml of the starting
mobile phase solvent for LC-ESI-MS/MS analysis (see below),
and extensively sonicated, centrifuged for 5 min at 5,000 g and
4°C, and the supernatant decanted or pipetted into an autoinjector vial (VWR, #46610-724) and capped (VWR, #89239-020)
for analysis.

Internal standards
Internal standards were from Avanti Polar Lipids (Alabaster,
AL) and were added to samples as a cocktail containing 250 pmol
each in 10 µl ethanol:methanol:water (7:2:1). Sphingoid base
and sphingoid base 1-phosphate standards were 17-carbon
chain-length analogs: C17-sphingosine, (2S,3R,4E)-2-aminoheptadec-4-ene-1,3-diol (d17:1-So); C17-sphingosine 1-phosphate,
heptadecasphing-4-enine-1-phosphate (d17:1-So1P). Standards for
N-acyl sphingolipids were C12-fatty acid analogs: C12-Cer, N(dodecanoyl)-sphing-4-enine (d18:1/C12:0); C12-Cer 1-phosphate,
N-(dodecanoyl)-sphing-4-enine-1-phosphate (d18:1/C12:0-Cer1P);
C12-SM, N-(dodecanoyl)-sphing-4-enine-1-phosphocholine (d18:1/
C12:0-SM); and C12-glucosylceramide, N-(dodecanoyl)-1-glucosyl-sphing-4-eine.

MS
Analysis was performed as described (13, 23). Briefly, for LCESI-MS/MS analyses, a Shimadzu Nexera LC-30 AD binary pump
system coupled to a SIL-30AC autoinjector and DGU20A5R degasser coupled to an AB Sciex 5500 quadrupole/linear ion trap
(QTrap) (SCIEX, Framingham, MA) operating in a triple quadrupole mode was used. Q1 and Q3 were set to pass molecularly
distinctive precursor and product ions (or a scan across multiple
m/z in Q1 or Q3), using N2 to collisionally induce dissociations in
Q2 (which was offset from Q1 by 30–120 eV); the ion source temperature set to 500°C. Q1 and Q3 precursor and product ion transitions are shown in Table 1.
Sphingolipids were separated by reverse-phase LC on a Supelco 2.1 × 50 mm Ascentis Express C18 column (Sigma, St. Louis,
MO) at 35°C using a binary solvent system (flow rate of 0.5
ml/min). Prior to injection, the column was equilibrated for
0.5 min with a solvent mixture of 95% mobile phase A1
(CH3OH:water:HCOOH, 58:41:1, v:v:v, with 5 mM ammonium
formate) and 5% mobile phase B1 (CH3OH:HCOOH, 99:1, v:v,
with 5 mM ammonium formate), and after sample injection (typically 5 l), the A1/B1 ratio was maintained at 95/5 for 2.25 min,
followed by a linear gradient to 100% B1 over 1.5 min, which was
held at 100% B1 for 5.5 min, followed by a 0.5 min gradient return to 95/5 A1/B1. The column was re-equilibrated with 95/5
A1/B1 for 0.5 min before the next run.

Lipid phosphate quantification
Total lipid phosphates were extracted and quantified as described (24). Briefly, lipids were extracted using a single-phase
Bligh-Dyer extraction as described above, and the extracts dried
down in a Speed-vac. Lipids were then resuspended in 3 ml of a
1:2 chloroform:methanol mixture and vortexed, 0.8 ml of water
added to form a single-phase solution, vortexed, and then 1 ml of
chloroform and 1 ml of water sequentially added and vortexed to
obtain a two-phase solution. Samples were then centrifuged at
3,000 g and the upper aqueous layer aspirated and discarded. A
fraction of the organic layer was then removed (typically 1.6 ml),
placed in a clean 13 × 100 mm borosilicate glass tube, and the
solvent evaporated in a Speed-vac. Once dried, 600 l of ashing
solution (1.8 N H2SO4, 1.4% HClO4 in water) were added to each
sample and to sodium phosphate standards (solutions containing 0.1–1 mM NaH2PO4). Samples and standards were then vortexed and placed on a 160°C heating block overnight. The next
day, samples and standards were allowed to cool and 0.9 ml of
water, 0.5 ml of 0.9% ammonium molybdate, and 200 l of 9.0%
ascorbic acid solution added sequentially with intermittent
vortexing. Samples and standards were then incubated at 45°C
for 30 min. Absorbance of a 200 l aliquot of each sample and
standard was measured at 600 nm with a microplate reader
(Bio-Tek).
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TABLE 1. MRM pairs, ionization parameters, and collision energies utilized for the LC-ESI-MS/MS
of sphingolipids
Q1 Mass (Da)

Q3 Mass (Da)

DP

300.5
302.5
380.4
382.4

282.3
284.3
264.4
266.4

100
100
90
90

510.7
538.7
564.7
566.7
594.7
622.8
648.9
650.9
676.9
678.9

264.4
264.4
264.4
264.4
264.4
264.4
264.4
264.4
264.4
264.4

80
80
80
80
80
80
80
80
80
80

43.5
46
48.5
48.5
51
53.5
56
56
58.5
58.5

672.6
700.7
726.7
728.7
756.7
784.8
810.9
812.9
838.9
840.9

264.4
264.4
264.4
264.4
264.4
264.4
264.4
264.4
264.4
264.4

80
80
80
80
80
80
80
80
80
80

43.5
46
48.5
48.5
51
53.5
56
56
58
58

675.7
703.8
729.8
731.8
759.9
787.9
813.9
815.9
841.9
843.9

184.4
184.4
184.4
184.4
184.4
184.4
184.4
184.4
184.4
184.4

80
80
80
80
80
80
80
80
80
80

43.5
46
48.5
48.5
51
53.5
56
56
58
58

Sphingoid bases
d18:1 Sph
d18:0 dihydro- Sph
d18:1 S1P
d18:0 dihydro-S1P
Ceramide acyl chain-length
C14:0
C16:0
C18:1
C18:0
C20:0
C22:0
C24:1
C24:0
C26:1
C26:0
Monohexosylceramide acyl chain-length
C14:0
C16:0
C18:1
C18:0
C20:0
C22:0
C24:1
C24:0
C26:1
C26:0
SM acyl chain-length
C14:0
C16:0
C18:1
C18:0
C20:0
C22:0
C24:1
C24:0
C26:1
C26:0

CE

21
21
25
25

DP, declustering potential; CE, collision energy.

RESULTS
Data normalization strategies
Robust analysis strategies rely on the ability to compare
relative levels of sphingolipids across different experimental groups, which might have vastly different inputs. For
example, one might have large amounts of normal tissue,
but have a very limited amount of a tumor. Therefore, it is
critical that MS data be internally (with internal standards)
and externally normalized. Tissue weight, protein concentration, and total lipid-phosphate content are routinely
used to externally normalize data with different amounts of
specimen input, and produce data of sphingolipid levels
relative to milligrams of tissue (if by weight), per microgram
of protein (if by protein concentration), or per total lipid
phosphate content. In sOCTrP, tissues are washed several
times prior to MS analysis, and we have suggested that tissues can be “wet-weighed” as a method to externally normalize data. However, it was important to assess the accuracy
of this strategy in faithfully reflecting initial tissue weights.
For these experiments, mouse livers were weighed and recorded following surgical extraction, placed in preweighed
tubes, washed with sOCTrP, and the tubes reweighed and
956
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recorded after washing. For analysis, data were plotted as
an XY-scatterplot with initial- and wet weights as axes. For
specimens weighing between 4.1 and 171 mg, as shown in
Fig. 1A, there was a strong linear relationship (R2 = 0.9986)
between initial and wet weights, which were statistically
correlated by a significant (P < 0.0001) Pearson productmoment correlation coefficient of 0.9993 and a mean residual error of 0.3 mg (Fig. 1A, inset). These results show
that wet weight is strongly correlated with tissue weight and
should be an acceptable method to obtain external normalization values for tissues.
A common method for normalizing sphingolipidomic
data involves measuring the protein concentration of lysates prepared from tissues being analyzed, and lipids are
normalized per milligram or microgram of protein. To examine the relationship between protein concentration and
wet weight, mouse liver specimens ranging in size from 3.3
to 130.0 mg were also wet weighed after sOCTrP, and then
resuspended in 1 ml of buffer containing 30 mM HEPES,
150 mM NaCl, 10% glycerol, 1 mM EDTA, and 0.1% Triton
X-100, homogenized, and sonicated on ice for three cycles
of 60 s sonication (60% power; microtip) with a Branson
probe sonicator (Branson Ultrasonics) and a 1 min rest on

Fig. 1. Correlation between wet weight and common data normalization measures. A–C: XY-scatterplots and Pearson correlation analysis
between initial weights and wet weights (A), protein concentrations and wet weights (B), and lipid phosphates and wet weights (C). For A,
mouse livers were weighed after removal (called initial weight), processed with sOCTrP, and weighed (called wet weight). In B, mouse livers
were processed with sOCTrP, wet weights were recorded, and then the tissues were resuspended in buffer, sonicated, centrifuged, and protein
concentrations of the supernatants determined using a Bio-Rad protein assay. In C, mouse livers were processed by sOCTrP; wet weights were
recorded; and then total lipid phosphates were extracted, resuspended, and absorbances recorded. Dotted lines are linear correlation fits of
variables, and the linear fit coefficients (R2), Pearson correlation coefficients (r), and P-values for Pearson correlation analysis (p) are shown
in each plot. In A, the bottom right inset shows the relative percent error across all weights measured. In A and B, residuals (milligrams) of
linear correlation fits are shown in the top left insets. Data were fit with Prism. P  0.05 was considered significant.

ice. The resulting homogenates were centrifuged at 12,000
g at 4°C, and protein concentrations of the supernatants
determined using a Bradford protein assay (Bio-Rad). As
shown in Fig. 1B, an XY-scatterplot with wet weight and protein concentration axes showed a strongly linear relationship (R2 = 0.9900) between variables and had a significant
(P < 0.0001) Pearson product-moment correlation coefficient of 0.995 and a mean residual error of 0.1 mg (Fig. 1B,
inset). These data suggest that wet weights and protein concentrations of tissue lysates are equally suitable and comparatively accurate methods to normalize data, even from
tissue specimens that do not contain OCT compound.
Lastly, we assessed the relationship between wet weight
and total lipid phosphates extracted and quantified from
mouse livers ranging from 11 to 56 mg. As shown in Fig.
1C, under the conditions used to extract lipid phosphates
(see the Materials and Methods), quantified levels were
strongly correlated (r = 0.9535, P = 0.0032) and linear (R2 =
0.9092) with wet weight.
Interference of OCT compound with data normalization
strategies
To accurately assess whether OCT compound interferes
with data normalization or MS, it was first important to estimate how much OCT compound ordinarily accompanies
biorepository tissue specimens. Tubes containing tissue
sections embedded in OCT compound were preweighed,
the tissues washed with sOCTrP, and the tubes reweighed
after the OCT compound had been removed. The difference between initial and final tube weight was assumed to
be an estimate of the amount of OCT compound contained in each tube. On average, there were 181.4 mg of
OCT compound (Fig. 2A, inset) with specimens weighing
between 1.8 and 39.7 mg (Fig. 2A), but OCT compound
content per tube ranged between 14.7 and 375.7 mg (Fig.

2A). As expected, there was a statistically significant negative correlation between tissue weight and OCT compound
content, with the smallest specimens containing higher
amounts of OCT compound (Fig. 2A). This is likely because tissues are embedded in standard size blocks and
then backfilled with OCT compound. Therefore, the proportion of OCT compound per tissue weight increases almost proportionally with smaller tissue specimens. These
results suggest that using raw tissue weight could dramatically skew external data normalization.
As protein concentration of tissue lysates was strongly
correlated with tissue weight (Fig. 1B), it was important to
establish whether OCT compound interfered with the standard colorimetric or spectrophotometric assays used to
determine protein concentration. Therefore, a series of
solutions containing OCT compound, at concentrations
that were expected based on the quantification of OCT
compound contained by biorepository specimens (Fig.
2A), were prepared, along with standard solutions containing BSA. As shown in Fig. 2B and C, OCT compound solutions had concentration-dependent absorbance changes
with Lowry and Bradford colorimetric protein assays, respectively. Moreover, OCT compound solutions had an
absorbance spectrum in water below 300 nm like those of
double stranded nucleic acids and proteins (Fig. 2D).
Therefore, these results show that OCT compound interferes with standard assays used to estimate protein and nucleic acid concentration, and these assays will likely be
unreliable when using samples containing large amounts
OCT compound relative to specimen size.
OCT compound interference with sphingolipid
quantification by LC-ESI-MS/MS
We have shown it is critical that OCT compound be
removed from tissue sections because of its interference
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Fig. 2. Ratios of OCT compound to tissue weights in
biorepository tissues sections and interference of OCT
compound with protein quantification and absorption
spectroscopy analysis. A: Lung tissues (n = 30) were
procured from the VCU TDAAC. Tubes were weighed,
the tissues were washed with sOCTrP, and then the
tubes were reweighed to estimate OCT compound in
each tube. Tissue weights were determined by weighing the empty tubes after OCT compound removal
and then verified using the wet weighing protocol.
The dashed line is a linear correlation fit analysis between OCT compound content and tissue weights,
and the Pearson correlation coefficient (r) and P-value
(p) are shown. Inset: OCT compound weight distribution across 30 lung tissue specimens. B, C: Solutions
(n = 3) were prepared containing BSA, OCT amounts
based on the data in A, and protein concentrations
measured with Lowry (B) or Bradford (C) assays. Absorbance was read on a plate reader at 595 nm. D: Absorption spectra of solutions containing dsDNA or
OCT compound. The quantity of dsDNA used is the
expected yield of DNA from 25 mg of lung tissue (Qiagen), and OCT compound amount was based on the
data in A.

with external data normalization strategies. However, it
was also important to examine whether OCT compound
impacted established LC-ESI-MS/MS sphingolipid quantification methods. Thus, 200 mg of mouse liver were resuspended in 2 ml of PBS, homogenized until fully
dispersed, and sonicated with a Branson probe sonicator
(three rounds of 1 min sonication on ice, 1 min rest on
ice). From this solution, six identical 300 l liver-homogenate replicates were prepared; to three replicates, 200 mg
of OCT compound were added (200 mg was based on
data shown in Fig. 2A), and 200 µl of water were added
to the other three replicates. One milliliter of methanol
was then added, and samples were stored at 80°C. Replicates were then processed in parallel and analyzed following lipid extraction and MS protocols as described
in the Materials and Methods. It was noted that, unlike
control samples with water, OCT compound-containing
replicates were cloudy in the single-phase lipid extraction solution, which could not be clarified with centrifugation. After overnight extraction, centrifugation, and
solvent evaporation, OCT compound-containing replicates had large insoluble pellets that could not be reconstituted in methanol even under vigorous and extensive
sonication. As shown in Fig. 3, OCT compound-containing samples had dramatic reductions in analyte peak
heights (Fig. 3A–E), total peak areas (Fig. 3F–I, insets),
and acyl-chain length peak areas (Fig. 3F–H). The effect
was not systematic or species- or acyl chain-length-specific, and affected SMs (Fig. 3A), ceramides (Fig. 3B),
monohexosylceramides (Fig. 3C), and sphingoid bases
(Fig. 3D, E). These results show that failure to remove
OCT compound from tissue specimens can impact the
reliable quantification of sphingolipid levels by LC-ESIMS/MS.
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sOCTrP validation
Because OCT compound interferes with multiple elements in the sphingolipidomic LC-ESI-MS/MS analysis
workflow, it was important to establish that the protocol
used to remove OCT compound did not affect determination of sphingolipid levels in tissues. Thus, mouse livers and lungs were used for validation experiments. First,
the effect of continuous sOCTrP cycles on signal decay
was examined using liver or lung tissues that had been
embedded in OCT compound. Tissues not embedded in
OCT compound or processed with sOCTrP were used as
controls. Given that large pellets remained in lipid extractions performed with OCT compound, a minimum
of three sOCTrP cycles were used to avoid damaging
LC columns or contaminating MS equipment with OCT
compound. Sample weights were used to normalize MS
data. Total levels of individual sphingolipids were assessed.
As shown in Fig. 4, successive sOCTrP cycles with lung tissues did not lead to significant reductions in the levels
of complex sphingolipids, including ceramides (Fig. 4A),
monohexosylceramides (Fig. 4B), and SMs (Fig. 4C), or
of the sphingoid bases, sphingosine (Sph) (Fig. 4D), S1P
(Fig. 4D), dihydrosphingosine (dihydro-Sph; Fig. 4D), or
dihydrosphingosine-1-phosphate (dihydro-S1P; Fig. 4D).
Similarly, successive sOCTrP cycles in liver tissues did not
significantly deplete ceramides (Fig. 4E), monohexosylceramides (Fig. 4F), SMs (Fig. 4G), Sph (Fig. 4H), or dihydro-Sph (Fig. 4H). However, a significant loss of S1P and
dihydro-S1P was observed in liver tissues with as few as
three sOCTrP cycles (Fig. 4H). Yet, after the initial loss of
signal of these lipids, there were no significant differences
in S1P or dihydro-S1P levels between control-sOCTrP and
OCT-sOCTrP tissues (Fig. 4H), suggesting that there is a
stable pool of these lipids within the tissues that remains

Fig. 3. Quantification of sphingolipids by LC-ESI-MS/MS in the presence or absence of OCT compound. LC-ESI-MS/MS multiple reaction monitoring pairs of indicated lipids (A–E) and corresponding integrated peak areas (F–I). Mouse livers were homogenized and sonicated as described in the Materials and Methods, split into six identical samples, and 200 mg of OCT compound were added to three samples
(red traces and bars) and water to the other three (blue traces and bars). All six samples were processed identically and analyzed by LC-ESIMS/MS as described in the Materials and Methods.

after the initial washes. Based on these data, three sOCTrP
cycles are sufficient to produce reliable results.
The effects of short-term storage in OCT compound and
processing with sOCTrP were examined. Lung and liver tis-

sues were stored for 4 months at 80°C. Experimental conditions were: 1) specimens snap-frozen and not processed
with sOCTrP (labeled “control”); 2) specimens that were
snap-frozen, thawed, and processed with sOCTrP (labeled
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Fig. 4. Effect of sOCTrP cycles on total sphingolipid levels. Mouse lungs (A–D) and livers (E–H) were processed with the indicated number
of sOCTrP cycles and the indicated sphingolipids quantified by LC-ESI-MS/MS. Data are expressed as picomoles of lipid per milligram of
tissue. In all groups, control (Cntrl) samples were snap-frozen tissues not stored in OCT compound. sOCTrP-processed samples were embedded in OCT compound. In D and H, the y axis scale is log2 base. Total levels of ceramide, monohexosylceramide (monohexosyl-Cer), and
SM are the sum of their C14:0, C16:0, C18:1, C20:0, C22:0, C24:1, C24:0, C26:1, and C26:0 acyl chain-length species. In A–H, Cntrl n = 10. In
A–D, five and seven cycles n = 6; nine cycles n = 3. In E and F, five and seven cycles n = 6; nine cycles n = 3. Box plots show medians (black
line) and whiskers of minimum to maximum. ****P  0.0005. ns, not significant.

“control-sOCTrP”); and 3) specimens that were embedded
in OCT compound, frozen, thawed, and then processed
with sOCTrP (labeled “OCT-sOCTrP”). Upon thawing,
“control” tissues were first weighed, and then immersed
in 1ml of ice-cold LC-MS grade methanol; control-sOCTrP
tissues were thawed, processed with sOCTrP, wet weighed,
and then placed in 1 ml of ice-cold LC-MS grade methanol;
“OCT-sOCTrP” tissues were thawed, processed with sOCTrP, wet weighed, and placed in 1ml of ice-cold LC-MS
grade methanol. An analytical balance was used for weighing, and it was critical to minimize errors in tissue weighing
by removing as much washing solution as possible from
each sample prior to weighing using wicks.
As shown in Figs. 5 and 6, respectively, short-term storage in OCT compound or processing with sOCTrP did not
result in significant deterioration of total sphingolipid levels in lung or liver tissues. Furthermore, when acyl chainlength-specific fluctuations were evaluated, there were no
significant changes between lung control, lung controlsOCTrP, and lung OCT-sOCTrP ceramides (Fig. 5A),
monohexosylceramides (Fig. 5B), SMs (Fig. 5C), Sph (Fig.
5D), S1P (Fig. 5D), dihydro-Sph (Fig. 5D), or dihydro-S1P
(Fig. 5D). Similar observations were made with most sphingolipids from liver tissues (Fig. 6). However, unlike lung
tissues, sOCTrP processing of control liver tissues, which
contain relatively large volumes of blood compared with
960
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lung (27), resulted in a significant decrease in the levels of
S1P and dihydro-S1P (Fig. 6D).
Analysis of human non-small cell lung cancer tumors
Two small cohorts of human lung adenocarcinomas
(LUADs; n = 5) and lung squamous cell carcinomas (LSCCs;
n = 5) stored in OCT compound were procured from the
VCU TDAAC. All tumors had matched adjacent uninvolved
tissues (AUTs) surgically removed at the time of tumor resection. All tissues had been cryopreserved in OCT compound
and were stored at 80°C. Specimens were received as fine
sections taken from OCT compound-embedded tumor
blocks. Upon thawing, tissues were processed with five cycles
of sOCTrP, weighed, placed in LC-MS grade ice-cold methanol, lipids extracted, and then analyzed by LC-ESI-MS/MS as
described in the Materials and Methods.
Levels of sphingolipids were altered in LUAD and LSCC
tumors compared with AUTs. Specifically, C24:1 ceramide
was significantly higher in LUADs (Fig. 7A) and LSCCs
(Fig. 7B). Importantly, however, ceramide changes were
not identical between LUADs and LSCCs, as only LSCC tumors had higher C16:0 ceramide (Fig. 7B). Interestingly,
although total ceramide levels were not significantly greater
in either disease compared with AUTs (Fig. 7A, B; insets),
total monohexosylceramides were significantly higher in
both diseases (Fig. 7C, D; insets). Moreover, there were

Fig. 5. Effect of sOCTrP on sphingolipid acyl chain-length species
in mouse lung tissues. Mouse lung tissue snap-frozen (blue bars),
snap-frozen and processed with sOCTrP (gray bars), or embedded
in OCT compound, frozen, and processed with sOCTrP (green
bars) were analyzed by LC-ESI-MS/MS and the indicated acyl chainlength species of ceramides (A), monohexosylceramides (B), SMs
(C), and Sph (D), S1P (D), dihydro-Sph (D), and dihydro-S1P (D)
quantified. Insets: Total levels of the indicated sphingolipids are the
sum of the acyl chain-length species and are expressed as picomoles
per milligram of tissue. In D, the y axis scale is log2 base. Box plots
show medians (black line) and whiskers of minimum to maximum.
ns, not significant. In A–D: Cntrl (blue bars), n = 6; control sOCTrP
(gray bars), n = 6; OCT-sOCTrP (green bars), n = 6.

Fig. 6. Effect of sOCTrP on sphingolipid acyl chain-length species
in mouse liver tissues. Mouse livers snap-frozen (blue bars), snapfrozen and processed with sOCTrP (gray bars), or embedded in
OCT compound, frozen, and processed with sOCTrP (green bars)
were analyzed by LC-ESI-MS/MS and the indicated chain-length of
ceramides (A), monohexosylceramides (B), SMs (C), and Sph
(D), S1P (D), dihydro-Sph (D), and dihydro-S1P (D) were quantified. Insets: Total levels of the indicated sphingolipids are the sum
of their acyl chain-length species and expressed as picomoles per
milligram of tissue. In D, the y axis scale is log2 base. Box plots show
medians (black line) and whiskers of minimum to maximum. ns,
not significant. ****P  0.0005. In A–D: Cntrl (blue bars), n = 10;
control sOCTrP (gray bars), n = 10; OCT-sOCTrP (green bars), n = 10.

dramatic differences between LUAD and LSCC tumors
and AUTs with regard to various monohexosylceramide
acyl chain-length species, such as C16:0 (4-fold higher in
LUADs; 6.8-fold higher in LSCCs), C24:1 (4.5-fold in

LUADs; 7.5-fold higher in LSCCs), and C24:0 (2.9-fold
higher in LUADs; 5.6-fold in LSCCs) (Fig. 7C, D). In stark
contrast to the significant changes in ceramides and monohexosylceramides, there were no alterations in total or acyl
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Fig. 7. Sphingolipid profiles of LUADs, LSCCs, and AUTs banked in OCT compound and processed with sOCTrP. LUADs (A, C, E, G),
LSCCs (B, D, F, H), and paired AUTs were obtained from the VCU TDAAC. Specimens had been embedded in OCT compound and cryogenically stored at 80°C. Tissues were processed with sOCTrP, weighed, and analyzed at the VCU Lipidomics Core. Lipid levels are in picomoles per milligram of tissue. The indicated acyl chain-length species of ceramide (A, B), monohexosylceramide (C, D), SM (E, F), and Sph
(G, H), S1P (G, H), dihydro-Sph (G, H), and dihydro-S1P (G, H) were quantified. Insets: Total levels of the indicated sphingolipids are the
sum of their acyl chain-length species. For LUADs (A, C, E,G), n = 5 tumors and n = 5 AUTs; LSCCs (B, D, F, H), n = 5 tumors and n = 5 AUTs.
Box plots show medians (black line) and whiskers of minimum to maximum. ns, not significant. *P  0.05; **P  0.01; **** P  0.0005.
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chain-length-specific SMs (Fig. 7E, F and insets) in either
disease. Similarly, no tumor/AUT differences were observed
for Sph (Fig. 7G), dihydro-S1P (Fig. 7G), S1P (Fig. 7H),
or dihydro-Sph (Fig. 7H). Data from AUTs were further
analyzed to assess differences in the AUT sphingolipid
profiles of patients with LUAD and LSCC. As shown in
Fig. 8, uninvolved lung tissues of subjects with LUAD or
LSCC did not show significant differences in total or acyl
chain-length-specific levels of ceramide (Fig. 8A and inset), monohexosylceramides (Fig. 8B and inset), SMs (Fig.
8C and inset), Sph (Fig. 8D), dihydro-Sph (Fig. 8D), S1P
(Fig. 8E), or dihydro-S1P (Fig. 8E).

ceramides (Fig. 9A), monohexosylceramides (Fig. 9B), SMs
(Fig. 9C), Sph (Fig. 9D), SiP (Fig. 9E), dihydro-Sph (data
not shown), or dihydro-S1P (data not shown). Remarkably,
a multiple-comparison ANOVA analysis that examined differences between lipid levels from patients one year and
any other year revealed no significant differences (Fig. 9).
Finally, a paired analysis between the oldest (2003) specimens and most recently acquired specimens (2019) did
not reveal any significant differences (Fig. 9).

Storage-related sphingolipid deterioration in OCT
compound-embedded lung tissues
To assess the decay of sphingolipids in long-term cryogenic storage, 73 normal lung tissue specimens that had
been frozen between 2003 and 2019 were processed with
sOCTrP and analyzed by LC-ESI-MS/MS. Data were plotted in an XY-scatterplot with total lipid levels and year frozen as the axes. A Pearson moment correlation analysis
revealed that there was not a significant age-related decay in

Much is to be learned of the roles that sphingolipids
play in human cancers, and large-scale studies that characterize sphingolipid metabolism alterations in tissues
can greatly enhance our ability to probe the mechanistic
underpinnings of these diseases. Yet, given current limitations in our ability to analyze tissues cryopreserved in
OCT compound, obtaining sufficient human specimens
for adequately powered studies can be challenging, oftentimes requiring prospective studies to acquire tissues

DISCUSSION

Fig. 8. Sphingolipid levels in AUTs of subjects with LUAD or LSCC. A–E: Secondary analysis of sphingolipid data from AUTs shown in Fig.
7. Comparison of total (insets) and acyl chain-length ceramides (A), monohexosylceramides (B), SMs (C), and Sph (D), S1P (E), dihydroSph (D), and dihydro-S1P (E) in the AUTs from patients with LUAD and LSCC. Insets: Total lipids are the sum of C14:0, C16:0, C18:0, C18:1,
C20:0, C22:0, C24:1, C24:0, C26:1, and C26:0 acyl chain-length species. All lipids are expressed in picomoles per milligram of tissue. Box plots
show medians (black line) and whiskers of minimum to maximum. ns, not significant.
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Fig. 9. Analysis of time-dependent effects on sphingolipid levels in tissues cryogenically stored in OCT compound for up to 16 years. XYscatterplots of total (sum of C14:0, C16:0, C18:1, C18:0, C20:0, C22:0, C24:1, C24:0, C26:1, and C26:0 acyl chain-length species) lipid levels
and the year tissues were cryopreserved in OCT compound. Each filled circle represents data from a single subject (n = 73). The x axis is the
year that tissues were collected, embedded in OCT compound, and frozen; the y axis is the total levels of ceramide (A), monohexosylceramide (B), SM (C), Sph (D), and S1P (E) in normal lung tissues of subjects. Pearson correlation analysis (Prism) revealed no significant
relationship between the year frozen and any of the lipids measured. ANOVA multi-comparison analysis (Prism) revealed no significant differences between the lipid levels of any given year and any other year (78 comparisons). ns, not significant. All lipids are expressed in picomoles per milligram of tissue. Blue lines are means with standard deviations.

directly from the surgical suite. In contrast, biorepositories already hold extensive tissue collections that can be
procured for retrospective studies. However, the broad
use of OCT compound for freezing specimens has been
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a barrier for MS analysis, given that polyvinyl alcohol and
polyethylene glycol in OCT compound readily ionize and
result in ion suppression and loss of signal (14–17, 21,
22). Here, we show that OCT compound is carried over

through all steps of single-phase Bligh-Dyer extractions
used for the extraction of sphingolipids from tissues,
which dramatically impacted their quantification with
LC-ESI-MS/MS (Fig. 3).
In contrast to the status quo for lipidomic analysis, there
are established methods for DNA, RNA, and proteomic
analysis of tissues embedded in OCT compound. For instance, laser capture microdissection is effective for extraction of RNA and DNA (19). Ether-methanol precipitation,
SDS-PAGE-based isolation, trichloroacetic acid precipitation, solid-phase extraction of glycopeptides, immobilization of proteins followed by washing, and washing samples
with ethanol are all methods that have been developed for
proteomics (14, 16, 20–22). OCT compound-embedded
tissues are also suitable for semi-quantitative analytical
methods like immunostaining or Western blotting following protein extraction by mechanical or chemical methods. Importantly, the accuracy and reproducibility of these
methods have led to the identification of numerous tumorspecific proteins and various potential druggable targets in
lung and prostate cancers (20, 22). However, these methods are unsuitable for lipidomic analysis because the physicochemical properties of sphingolipids and proteins are
vastly different, and any method that utilizes detergents
or organic solvents to remove OCT compound will result
in stripping or the extraction of sphingolipids into the
organic phase, leading to lipid-specific depletion and introducing methodology-related artifacts. Given the demonstrated importance of sphingolipids in the etiology of
human diseases, developing methodology for MS sphingolipid profiling of OCT compound-cryopreserved tissues is
warranted. Therefore, we have developed a method for LCESI-MS/MS sphingolipidomic analysis of human specimens cryopreserved in OCT compound. Our method is
simple, inexpensive, and 40 samples in 1 day can be routinely processed.
In addition to previously shown experimental barriers
in the analysis of OCT compound-embedded specimens
(14–17, 21, 22), here we show that OCT compound interfered with assays used for normalization of MS data. First,
we found an inversely proportional relationship between
the amount of OCT compound and tissue size in biorepository-procured tissue specimens (Fig. 2A). This was not
unexpected, as specimens of different sizes are placed
in similarly sized cryopreservation trays. Thus, smaller
specimens occupy a smaller proportion of a frozen OCT
compound-tissue block. Consequently, if OCT compound
is not removed prior to weighing tissues, the net weight
cannot be used for data normalization as their mass is proportionally mostly OCT compound. In our experiments,
we found that this is particularly critical for tissue OCT
compound specimens weighing 10 mg or less, as these had
275–375 mg of OCT compound (Fig. 2A). Failure to remove OCT compound would result in significant errors in
data normalization. Second, tissue extract protein concentrations are commonly used to normalize MS data (23,
26–31). However, we found that OCT compound interferes
in a concentration-dependent manner with Bradford
and Lowry reagents (Fig. 2B, C). The concentrations of

OCT compound tested in these assays were based on the
quantities of OCT compound found in tissue sections
(Fig. 2A). Third, OCT compound has an absorbance spectrum that overlaps with DNA and protein spectra (Fig.
2D). Therefore, in combination, these results indicate that
OCT compound must be removed from tissue sections if
weights or protein concentrations of tissue extracts will be
used to externally normalize MS data. However, this can
be easily remedied if OCT compound is removed from tissues with sOCTrP, and we demonstrate that tissue weights
prior to sOCTrP washing closely correlated with postsOCTrP wet weights (Fig. 1A). Moreover, wet weights
closely correlated with the protein concentration of extracts (Fig. 1B) and total lipid phosphates prepared from
tissues (Fig. 1C). We also demonstrate that it is safe to use
Kimwipe wicks to fully remove all wash solution from tissues in the final steps of sOCTrP, which can increase the
accuracy of tissue weighing. Therefore, tissue wet weights
are a suitable normalization strategy for OCT compoundembedded specimens.
Validation experiments with mouse tissues demonstrated that storage in OCT compound and sOCTrP processing did not deplete most sphingolipids analyzed.
Specifically, in mouse lung tissues, there were no changes
in ceramides, monohexosylceramides, or SMs with C14:0,
C16:0, C18:1, C20:0, C22:0, C24:1, C24:0, C26:1, and C26:0
chain-lengths, or of Sph, dihydro-Sph, S1P, and dihydroS1P. In mouse liver tissues, ceramides, monohexosylceramides, SMs, Sph, and dihydro-Sph were also unchanged
by sOCTrP. However, washing fresh mouse liver tissues
with sOCTrP did result in a significant depletion of S1P
and dihydro-S1P. One possibility for this depletion is that
as there is a much larger blood volume in livers than in
lungs (25), and blood contains some of the highest physiological levels of S1P (32, 33). Therefore, reduction in S1P
is likely due to removal of blood from the liver tissues by
sOCTrP. This is consistent with the observation that S1P
levels were reduced after the initial three sOCTrP cycles
but remained constant up to seven sOCTrP cycles (Fig.
4H). We suggest that S1P quantified in sOCTrP-washed livers is tissue-associated and likely membrane embedded.
Nevertheless, in contrast to these observations in liver,
there was no reduction in S1P or dihydro-S1P in lung tissues. Given these data, sOCTrP should be adequate for the
analysis of sphingolipids such as ceramides, monohexosylceramides, SMs, Sph, and dihydro-Sph from lung and liver
tissues. For lung tissues, our data suggest that sOCTrP is an
amenable method for S1P analysis, but evaluation of S1P
levels in tissues processed with sOCTrP should be interpreted with caution. However, in validation experiments,
there were no significant differences in S1P or dihydro-S1P
between control-sOCTrP- and OCT-sOCTrP-processed tissues. Thus, in cases where biorepository specimens have
paired normal tissues, we suggest that so long as tumor and
normal tissues are processed using the same number of
sOCTrP cycles, S1P data might be informative.
Upon validation of sOCTrP, a small scale lipidomic analysis of tissues from patients with the two most common
non-small cell lung cancer histological subtypes, LUAD
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and LSCC, was conducted. Data from five human subjects
per disease with matched AUTs showed tumors had significant alterations in ceramides (C16:0 and C24:1 acyl chainlengths) and monohexosylceramides (C16:0, C24:1, and
C24:0 acyl chain-lengths). A disease-specific alteration was
also observed, as C16:0 acyl chain-length ceramides were
elevated only in LSCC and not in LUAD. Currently, there
are no LSCC-specific molecular targets. Importantly, however, not all sphingolipids were higher in tumors, as SMs of
all acyl chain-lengths and Sph were unaltered in either disease. Furthermore, a secondary analysis revealed that there
were no significant differences between adjacent uninvolved lung tissues of subjects with adenocarcinomas or
squamous cell carcinomas. These data suggest there are
specific sphingolipid metabolism alterations in the tumors
of patients with non-small cell lung cancer. This is consistent with the expanding body of evidence demonstrating
that sphingolipid alterations are observed in many cancers.
As these changes are thought to influence various steps
along the carcinogenic pathway, and in progression, metastasis, and the development of multi-drug resistance (2, 3,
10), new tools, such as sOCTrP, that permit medium to
large scale analysis of specimens from human subjects
should grant further insight into the role that sphingolipid
alterations play in the etiology these diseases. Moreover, as
biorepositories already hold large numbers of specimens,
these studies can be retrospective in nature, which should
accelerate the collection of substantial volumes of data
without the design and approval of prospective studies. Importantly, using 73 normal tissue specimens, we have shown
that complex sphingolipids and sphingoid bases are stable
when cryopreserved for 16 years. Moreover, this analysis
showed that the normal lung levels of sphingolipids in
many individuals are remarkably similar.
Few studies have reported measurements of sphingolipid levels in human lung specimens. However, C16:0,
C18:0, C20:0, and C22:0 acyl chain-length ceramides have
been measured in biopsies from freshly explanted lungs of
subjects with pulmonary hypertension or with cystic fibrosis
(34), where patients with pulmonary hypertension were
considered “normal” subjects. Ceramide levels between
these normal subjects and the adjacent uninvolved lung tissues in our study are comparable. These results suggest
that tissues stored in OCT compound and processed with
sOCTrP have ceramide levels similar to those of fresh human lung tissues. Moreover, it is reasonable to assume that
any differences between our normal subjects could be biological and not of experimental origin. Nevertheless, these
results further validate the utility of our protocol, as comparative studies between several diseases could be used to
establish the molecular origins of sphingolipid alterations
and define common mechanistic themes that might provide
druggable targets. These types of studies could be highly
insightful in cancers and cardiovascular and inflammatory
diseases where sphingolipids are known to play important
roles (2, 3, 10).
Data availability
All data are contained within the article.
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